文献速递消化道肿瘤放疗放疗物理与技术

针对局部晚期胰腺癌的3次分割SBRT的1期剂量递增研究

Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-03-12

该研究为2016至2019年在纪念斯隆-凯特琳癌症中心和科罗拉多大学开展的两项平行1期剂量递增试验,纳入24例诱导化疗后无远处进展的局部晚期胰腺癌患者,接受3次分割SBRT,剂量为27、30、33 Gy,未观察到≥3级毒性,3次分割剂量递增至33 Gy未出现剂量限制性毒性且生活质量无损害。

要点

  • 3次分割SBRT剂量递增至33 Gy未出现剂量限制性毒性,无≥3级毒性。
  • 2年局部失败率31.7%,远处转移率70.2%,无进展生存率20.8%,总生存率29.2%。
  • 3个月和6个月生活质量评估显示无损害。

核心结论

  • 对于经选择的局部晚期胰腺癌患者,3次分割剂量递增至33 Gy未出现剂量限制性毒性,生活质量无损害,疾病结局与传统放疗相当。
  • 需要进一步探索SBRT方案以最大化肿瘤控制并实现与全身治疗的有效整合。

研究设计与样本

  • 2016至2019年在纪念斯隆-凯特琳癌症中心和科罗拉多大学开展的两项平行1期剂量递增试验。
  • 纳入组织学确诊的局部晚期胰腺癌患者,要求至少2个月诱导化疗后无远处进展。
  • 采用改良3+3设计,3次分割基于直线加速器的SBRT,剂量水平为27、30和33 Gy。
  • 剂量限制性毒性定义为90天内≥3级胃肠道毒性,按美国国家癌症研究所不良事件通用术语标准第4版评分。
  • 共纳入24例连续患者(27 Gy组9例,30 Gy组8例,33 Gy组7例)。

主要发现

  • 中位年龄67岁(范围52-79),12例(50%)为头/钩突部肿瘤,中位肿瘤大小3.8 cm(范围1.1-11),CA19-9中位60 U/mL(范围1-4880)。
  • 所有患者接受化疗,中位时间4个月(范围1.4-10)。
  • 未观察到≥3级毒性。
  • 2年局部失败率、远处转移率、无进展生存率和总生存率分别为31.7%(95%CI 8.6%-54.8%)、70.2%(95%CI 49.7%-90.8%)、20.8%(95%CI 4.6%-37.1%)和29.2%(95%CI 11.0%-47.4%)。
  • 3个月和6个月生活质量评估显示无损害。

关键数值与推荐

  • 剂量水平为27、30和33 Gy,分3次照射。
  • 剂量限制性毒性定义为90天内≥3级胃肠道毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步探索SBRT方案以最大化肿瘤控制并实现与全身治疗的有效整合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal dose and fractionation of stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (LAPC) have not been defined. Single-fraction SBRT was associated with more gastrointestinal toxicity, so 5-fraction regimens have become more commonly employed. We aimed to determine the safety and maximally tolerated dose of 3-fraction SBRT for LAPC. METHODS AND MATERIALS: Two parallel phase 1 dose escalation trials were conducted from 2016 to 2019 at Memorial Sloan Kettering Cancer Center and University of Colorado. Patients with histologically confirmed LAPC without distant progression after at least 2 months of induction chemotherapy were eligible. Patients received 3-fraction linear accelerator-based SBRT at 3 dose levels, 27, 30, and 33 Gy, following a modified 3+3 design. Dose-limiting toxicity, defined as grade ≥3 gastrointestinal toxicity within 90 days, was scored by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. The secondary endpoints included cumulative incidence of local failure (LF) and distant metastasis (DM), as well as progression-free and overall survival PFS and OS, respectively, toxicity, and quality of life (QoL) using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and the pancreatic cancer-specific QLQ-PAN26 questionnaire. RESULTS: Twenty-four consecutive patients were enrolled (27 Gy: 9, 30 Gy: 8, 33 Gy: 7). The median (range) age was 67 (52-79) years, and 12 (50%) had a head/uncinate tumor location, with a median tumor size of 3.8 (1.1-11) cm and CA19-9 of 60 (1-4880) U/mL. All received chemotherapy for a median of 4 (1.4-10) months. There were no grade ≥3 toxicities. Two-year rates (95% confidence interval) of LF, DM, PFS, and OS were 31.7% (8.6%-54.8%), 70.2% (49.7%-90.8%), 20.8% (4.6%-37.1%), and 29.2% (11.0%-47.4%), respectively. Three- and 6-month QoL assessment showed no detriment. CONCLUSIONS: For select patients with LAPC, dose escalation to 33 Gy in 3 fractions resulted in no dose-limiting toxicities, no detriments to QoL, and disease outcomes comparable with conventional RT. Further exploration of SBRT schemes to maximize tumor control while enabling efficient integration with systemic therapy is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Reyngold M, Karam SD, Hajj C, et al. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 36918130. doi:10.1016/j.ijrobp.2023.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。